- Non-inferior decreases in A1c levels;
- Significantly less hypoglycemia;
- Significant decreases in fasting blood glucose levels; and
- Significant weight advantage.
Shares of insulin maker Mannkind plummeted on news of a proposed stock split, staffing changes and a new iteration of its insulin.
Mannkind stock is suffering, and the company appears to be in trouble.
Other movers included Mannkind, Perrigo and Bristol-Myers Squibb.